ClinicalTrials.gg
RecruitingNCT05836324Updated Jul 23, 2026

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of INCA33890 and bevacizumab in Solid Tumors, Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Incyte Corporation. Recruiting at 39 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
570
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

02

Conditions studied

  • Solid Tumors
  • Advanced Solid Tumors
  • Metastatic Solid Tumors

Keywords

  • Solid Tumors
  • INCA33890
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • or cytologically confirmed advanced or as defined in the protocol.
  • Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study.
  • performance status score of 0 or 1.
  • Willingness to undergo pre- and on-treatment tumor (core or excisional). Biopsies are mandatory depending on the cohorts.
  • Presence of according to v1.1.

Exclusion criteria

Exclusion Criteria:

  • Any known additional that is progressing or requires active treatment, or history of other malignancy within 2 years.
  • Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy.
  • Has active disease requiring systemic with .
  • Brain or untreated or that have progressed.
  • History of organ transplant, including stem cell transplantation.
  • History of or uncontrolled cardiac disease.
  • Active , active , or positive.
  • Is on chronic systemic steroids (> 10 mg/day of prednisone or equivalent).
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
  • Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment.
  • Significant concurrent, uncontrolled medical condition, eg:

    • Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis.
    • Gastrointestinal: Any bowel obstruction within 60 days prior to C1D1.
  • Participants with adequate laboratory values within the protocol defined ranges.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
570 participants (estimated)

Study arms

  • Experimental
    Part 1a - Dose Escalation Monotherapy

    INCA33890 will be administered at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890

  • Experimental
    Part 1b-Dose Expansion Monotherapy

    INCA33890 will be administered at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890

  • Experimental
    Part 2a - Dose Escalation Combination Therapy - Group 1

    INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab

  • Experimental
    Part 2a - Dose Escalation Combination Therapy - Group 2

    INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab · Drug: FOLFIRI

  • Experimental
    Part 2a - Dose Escalation Combination Therapy - Group 3

    INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab · Drug: FOLFOX

  • Experimental
    Part 2a - Dose Escalation Combination Therapy - Group 4

    INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: Cetuximab

  • Experimental
    Part 2a - Dose Escalation Combination Therapy - Group 5

    INCA33890 will be administered in combination with ADG126 at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: ADG126

  • Experimental
    Part 2b - Dose Expansion Combination Therapy - Group 1

    INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab

  • Experimental
    Part 2b - Dose Expansion Combination Therapy - Group 2

    INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab · Drug: FOLFIRI

  • Experimental
    Part 2b - Dose Expansion Combination Therapy - Group 3

    INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: bevacizumab · Drug: FOLFOX

  • Experimental
    Part 2b - Dose Expansion Combination Therapy - Group 4

    INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: Cetuximab

  • Experimental
    Part 2b - Dose Expansion Combination Therapy - Group 5

    INCA33890 will be administered in combination with ADG126 at the protocol-defined dose based on cohort assignment.

    Drug: INCA33890 · Drug: ADG126

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs)

    Time frame: Up to 28 days

  2. Treatment Emerging Adverse Events (TEAEs)

    Time frame: Up to 2 years

  3. TEAEs leading to dose modification or discontinuation

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective response Rate

    Time frame: 2 years

  2. Disease Control Rate

    Time frame: 2 years

  3. Duration of Response

    Time frame: 2 years

  4. Pharmacokinetics Parameter : Cmax of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  5. Pharmacokinetics Parameter : Tmax of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  6. Pharmacokinetics Parameter : Cmin of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  7. Pharmacokinetics Parameter : AUC(0-t) of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  8. Pharmacokinetics Parameter : AUC 0-∞ of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  9. Pharmacokinetics Parameter : CL of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  10. Pharmacokinetics Parameter : Vz of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

  11. Pharmacokinetics Parameter : t1/2 of INCA33890

    Time frame: Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up

07

Study locations

36 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for May 2029, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
May 1, 2023
StartActual
Jul 24, 2023
Primary completionEst.
May 3, 2029
CompletionEst.
May 3, 2029
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05836324
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Jul 24, 2023
Primary completion
May 3, 2029 (estimated)
Completion
May 3, 2029 (estimated)
Last update
Jul 23, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890

Start the discussion